Transcelerate Biopharma Inc

Nonprofit profile at a glance

EIN
460886344
IRS 990 coverage
2013–2025
Forms available
Form 990 2025
Location
West Conshohocken, PA, USA
Phone
4845391230
Rating
67
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Medical Research N.E.C.

Official website

Reported finances

Revenue
$34,242,546
Expenses
$33,032,304
Assets
$55,072,425
Liabilities
$35,380,185

Source: IRS Form 990. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

38 people listed

Executive titles in this filing

  • JANICE CHANG (CEO)

Highest reported compensation

  • JANICE CHANG (CEO): $1,227,289 total reported compensation
  • ALLISON CUFF SHIMOOKA (COO): $717,449 total reported compensation
  • JENNIFER BURGESS (VP, GLOBAL COMM & ENGAG (THRU 7/2025)): $537,229 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The organization's mission is to collaborate across the global biopharmaceutical r&d community to identify, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines.

What it reported doing in 2025

In 2025, transcelerate delivered practical solutions to simplify trial design and execution, strengthen quality, and reduce burden across the r&d ecosystem. The approach combined rapid improvements for immediate implementation with long-term solutions to help promising therapies reach patients more quickly and safely.the organization led 12 active initiatives in 2025 and launched more than 60 tools and solutions across three areas of focus:- transforming connectivity: redefining how research and care interact- information sharing and reuse: leveraging existing data for faster development- innovative trial design: putting patients at the heart of clinical trials.highlights of 2025 progress:- digital data flow (ddf): sponsors continued to adopt ddf while growing interest from solution providers showed that digital protocol innovation is moving from early pilot to everyday practice.- ich e6(r3) support: fifteen practical tools gave the industry ways to adapt to much-anticipated new guidance on good clinical practice earning wide media coverage along the way.- clinical data sharing: usage of transcelerate's datacelerate platform more than doubled, demonstrating the growing impact of data reuse to reduce burden and improve trial design.- patient safety reporting: a manuscript in a prominent journal and dialogue with multiple health authorities marked crucial first steps toward modernizing individual case safety reporting. - embedded pragmatic trials: transcelerate published a new resource guide and in collaboration with the fda released a public summary of a joint exercise to identify actionable opportunities to scale the use of pragmatic elements.transcelerate health authority dialogue expanded across four continents with continued focus on productive collaboration. The organization also partnered with a variety of outside organizations, including with the tufts center for the study of drug development (csdd) to publish a benchmarking study on protocol complexity.- transcelerate global reach and presence expanded in 2025. Highlights included hosting 8 public webinars reaching 7,000+ professionals, coverage in 50+ publications, and presentations at more than 20 conferences across north america, europe, asia, and south america.the organization's work in 2025 was and will continue to be oriented around a vision of seamless convergence of research and care, so that trial participation becomes a natural part of healthcare processes.

Operating model

Revenue model
Earned-program. 96% of the money available for current operations came from fees and other program revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - The filed numbers largely add up and most voting board members are independent. Some filing-based governance responses are negative or unanswered and expenses are high relative to revenue.

Rating breakdown

  • Financial Efficiency: 57
  • Transparency & Controls: 71
  • Accountability: 83
  • Sustainability: 35
  • Growth: 100

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 62%; rating input score 62
  • Program expense ratio: 66.7%; rating input score 67
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
  • Pay-setting controls: 2 of 6 controls in place; rating input score 33
    • Compensation committee: Missing
    • Independent consultant: Missing
    • Other Form 990s reviewed: Missing
    • Written employment contract: Pass
    • Compensation survey or study: Missing
    • Board or committee approval: Pass
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 95.2%; rating input score 95; 25th percentile among comparable filings
  • Governance controls: 6 of 9 controls in place; rating input score 67
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Fail
    • CEO compensation review process: Pass
    • Other executive compensation review process: Pass
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: 3.5%; rating input score 39; 39th percentile among comparable filings
  • Total-asset coverage ratio: 1.67; rating input score 45; 45th percentile among comparable filings
  • Liabilities to assets ratio: 0.64; rating input score 17; 17th percentile among comparable filings
  • Officer compensation ratio: 13.4%; rating input score 15; 15th percentile among comparable filings

Growth

  • Program expense growth: 7.3% per year; rating input score 100; 55th percentile among comparable filings
  • Revenue growth: 6.6% per year; rating input score 100; 54th percentile among comparable filings
  • Asset growth: 5.4% per year; rating input score 100; 37th percentile among comparable filings

Details

  • Where the money goes: 62% of revenue deployed · 66.7% of spending went to programs
  • Governance: 20 of 21 board members independent · 6 of 9 filing controls reported
  • Programs: 1 filed program accomplishment · $22M in reported program spending
  • Leadership: top reported pay $1.2M · 38 people listed · 2 of 6 pay-setting controls reported
  • Highest-paid contractors: 5 contractors listed · $15.9M reported
  • Consistency: 27 of 27 current checks pass
  • Schedules: 4 filed schedules · includes executive pay
  • Filing history: 13 filing years from 2013 to 2025
  • Contacts: How to reach this organization
  • Money network: 7 filed money-flow records
  • Related organizations: 1 filed related-organization link
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.
  • Staff and benefit plans: Retirement and health plans the organization files with the Department of Labor, and the people in them.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Review — Accountability: Governance controls: 2 of 8 not reported.
  • Moderate — Sustainability: Operating margin scored 39/100.
  • Moderate — Sustainability: Total-asset coverage ratio scored 45/100.
  • High — Sustainability: Officer compensation ratio scored 15/100.
  • High — Sustainability: Liabilities to assets ratio scored 17/100.